Printer Friendly

SENETEK PLC ANNOUNCES COMPLETION OF INITIAL STAGE OF MAJOR FUNDING

 SENETEK PLC ANNOUNCES COMPLETION OF INITIAL STAGE OF MAJOR FUNDING
 ST. LOUIS, Oct. 13 /PRNewswire/ -- Senetek PLC (NASDAQ: SNTYE), through its President and CEO Dr. Gerlof Homan, announced the completion of the initial stage of a major funding.
 This phase represents $3,900,000 in private equity financing. Homan stated that the funds have been and will be used for working capital including expenditure on next phase development in preparation for the finalization of joint venture and/or licensing agreements for major territories covering the marketing rights to the company's male sexual dysfunction product.
 The male sexual dysfunction product is currently undergoing testing in Denmark and the United Kingdom with the objective of securing registration in Europe. Testing is also planned in Thailand to open the large Asian market.
 Development of Senetek's Factor X continues to be undertaken by Procter & Gamble Company under a worldwide license agreement. Factor X is a product designed to ameliorate certain skin conditions including premature aging.
 An Alzheimer's Diagnostic product continues to provide promising indications. One of Europe's best-known pharmaceutical organizations is currently testing the product with a view to entering into a joint development agreement.
 For more information about Senetek PLC, contact Homan at 314-542-2202, or Dennis Nebbe at 319-268-1702.
 -0- 10/13/92
 /CONTACT: Dr. Gerlof Homan, 314-542-2202, or Dennis Nebbe, 319-268-1702, both of Senetek/
 (SNTYE) CO: Senetek PLC ST: Missouri IN: MTC SU:


EA-BN -- AT007 -- 9179 10/13/92 09:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1992
Words:240
Previous Article:MCI OFFERS SERVICE IN WAKE OF SPRINT OUTAGE
Next Article:IMC FERTILIZER REPORTS FIRST QUARTER EARNINGS
Topics:


Related Articles
SENETEK PLC ANNOUNCES APPROVAL TO BEGIN FORMAL CLINICAL TRIALS OF MALE SEXUAL DYSFUNCTION PRODUCT
SENETEK PRESIDENT ISSUES STATEMENT ON COMPANY'S PROGRESS
SENETEK RECEIVES NOTICE FROM ORTHO PHARMACEUTICAL
SENETEK ANNOUNCES NEW DIVISION PRESIDENT OF RESEARCH AND DEVELOPMENT
Senetek Reports Third-Quarter and Nine-Month Results
Senetek PLC's Chief Scientist Purchases 200,000 Shares of SNTKY Common Stock
Senetek Reports Third-Quarter and Nine-Month Results
Senetek Reports Fourth-Quarter and 1997 Year-End Results
Senetek PLC Announces Investor Conference Call on March 22.
Senetek PLC Announces Q2 Financial Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters